It's all noise. The ultimate fate of the company will be determined in clinical trials, likely next year. The announcement of a clinical trial start date will see the stock much higher than it is now (double or so would be my guess) and that point in time will then present investors with a choice that essentially has a binary outcome.... zero, or moonshot investment of a lifetime.
News 
Market Data 
Discover 
AI
